Clinical Trial Update: Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating diindolylmethane (DIM) supplements to increase the 2-OHE1/16 estrogen metabolite ratio in breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Diindolylmethane (DIM) supplement (diindolylmethane)

Snippet

Sponsor: Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED